Notice Regarding Appointment of New External Directors

Tokyo, Japan and London, UK, 16 May 2018 – Sosei Group Corporation ("Sosei" or the "Company"; TSE Mothers Index: 4565), the world leader in GPCR medicine design and development, today announced that at the Board of Directors meeting held on 15 May 2018, the Company decided, based on the resolution of the Nomination Committee, to submit the following candidates as new External Directors for approval at the 28th Ordinary General Meeting of Shareholders to be held on 22 June 2018.

- Dr Michael Hayden, former Global R&D President and Chief Scientific Officer at Teva Pharmaceuticals;
- Mr Kuniaki Kaga, former Board Director, Representative Director and Senior Managing Executive Officer at Mitsubishi Tanabe Pharma Corporation; and
- Dr David Roblin, former Senior Vice President, Head of Research, and Chief Medical Officer Europe R&D at Pfizer Inc.

1. Purpose of Appointing New External Directors

To enhance the supervisory function of the Board of Directors, provide experienced oversight of our research and development pipeline, and improve management transparency, with the aim of enhancing our overall corporate governance system.

2. Newly Appointed External Director Candidates

2.1. Name and professional history

Name	Professional history	
Dr Michael Hayden (born 21 Nov. 1951)	Jan. 1990	Founder and Board Member, Canadian Genetic Diseases Network
	Jul. 1991	Professor of Medical Genetics, the University of British Columbia (to the present)
	Jan. 1993	Director, the Center for Molecular Medicine and Therapeutics
		Senior Scientist, the Center for Molecular Medicine and Therapeutics (to the present)
	Jan. 1996	Director, Neurovir Inc.
	Jun. 1998	Director, Xenon Pharmaceuticals (to the present)
	Jan. 2000	Canada Research Chair, Human Genetics and Molecular Medicine (to the present)
	Mar. 2003	Killam Professor, the University of British Columbia (to the present)
	Nov. 2011	Distinguished Professor, the National University of Singapore (to the present)
	Nov. 2011	Director, the Translational Laboratory in Genetic Medicine of the Agency for Science, Technology and Research under the Ministry of Trade and Industry of Singapore (to the present)
	May 2012	Global R&D President and CSO, Teva Pharmaceuticals (retired December 2017)
Mr Kuniaki Kaga (born 1 Sep. 1951)	Apr. 1975	Joined Mitsubishi Kasei Kogyo Kabushiki Kaisha (the company name has been changed to Mitsubishi Chemical Corporation)
	Jun. 2004	Deputy Director and General Manager of Healthcare Planning Department, Mitsubishi Chemical Corporation
	Oct. 2005	Deputy Director, Mitsubishi Chemical Holdings Corporation
		General Manager of Healthcare Planning
	Jun. 2006	Executive Officer and General Manager of Healthcare Strategy Office, Mitsubishi Holdings Corporation

Mr Kuniaki Kaga (born 1 Sep. 1951) (cont'd)		Executive Officer, Head of Healthcare Business Domain, and General Manager of Healthcare Planning Office, Healthcare Business Domain, Mitsubishi Chemical Corporation
	Jun. 2009	Board Director, Mitsubishi Tanabe Pharma Corporation
	Jun. 2010	Representative Director, Managing Executive Officer, General Manager of International Business Department of Mitsubishi Tanabe Pharma Corporation
	Apr. 2012	Representative Director, Senior Managing Executive Officer, General Manager of Research Division and International Business Department of Mitsubishi Tanabe Pharma Corporation
	Apr. 2014	President and Representative Director, The KAITEKI Institute, Inc. and Board Director, Mitsubishi Tanabe Pharma Corporation Board Director, The KAITEKI Institute, Inc.
	Feb. 2015	President and Representative Director, The KAITEKI Institute, Inc.
	Apr. 2018	Adviser, Mitsubishi Chemical Corporation (to the present)
Dr David Roblin (born 25 Sep. 1966)	Apr. 1991	Clinical practice at St George's and St Bartholomew's Hospitals in the United Kingdom
	Sep. 1995	Global R&D Associate Director and Project Clinician, Pfizer Inc.
	Apr. 1997	Head of Anti-infective Therapy Area, Bayer Pharma
	Jun. 1999	Global R&D Executive Director, Head of GI & GU Therapy Area, Pfizer Inc.
	Jun. 2007	Worldwide Clinical Head of the Respiratory Therapy Area, Pfizer Inc.
	Dec. 2008	Senior Vice President, Head of Research, Site Head, Chief Medical Officer Europe R&D, Pfizer Inc.
	Apr. 2011	Chief Medical Officer, Creabilis
	Sep. 2013	Honorary Professor of Medicine, Swansea University (to the present)
	Feb. 2014	Director, The Francis Crick Institute COO, Scientific Translation
	Jun. 2014	Co-founder and Non-Executive Chairman, RCP Pharma LLP (to the present)
	Jun. 2015	Honorary Professor of Translational Medicine, St George's Hospital Medical School (to the present)
	Feb. 2017	Chairman of Scientific Translation, The Francis Crick Institute
	Feb. 2017	Chief Operating Officer, Chief Medical Officer, R&D President, Summit Therapeutics plc.
	Apr. 2017	Fellow of The Academy of Medical Sciences

2.2. Reasons for Appointment

We expect the three individuals to serve as competent External Directors for the reasons below and provide extensive suggestions concerning all aspects of the Company's corporate management, based on their considerable experience as senior executives and Directors for large publicly-listed international pharmaceutical companies.

- Dr Michael Hayden has had a distinguished career as an academic and researcher in the field of genetic medicine, as well as in the pharmaceutical industry, most notably as President of R&D and Chief Scientific Officer at Teva. The Company believes that he will leverage his extensive experience and specialized knowledge to further strengthen the Company's oversight of its R&D pipeline and so proposes his appointment as External Director.
- Mr Kuniaki Kaga has held several important senior positions at leading chemical and pharmaceutical companies in Japan, including Mitsubishi Chemical and Mitsubishi Tanabe Pharma. The Company believes that he will leverage his extensive experience and specialized knowledge to further strengthen the Company's overall management system and so proposes his appointment as External Director.

- Dr David Roblin gained clinical experience as a physician, and later followed with a distinguished career in the pharmaceutical industry, most notably as SVP and Head of R&D for Pfizer in Europe. The Company believes that he will leverage his extensive experience and specialized knowledge to further strengthen the Company's oversight of its R&D pipeline and so proposes his appointment as External Director.

3. Current Directors Seeking to be Reappointed

Shinichi Tamura, Representative Executive Officer
Peter Bains, Representative Executive Officer
Tomohiro Tohyama, External Director
Julia Gregory, External Director

4. External Directors Scheduled to Retire

Declan Doogan, External Director

Ends-

Enquiries:

Sosei +44 (0) 7912 892 199
Chris Cargill, Head of Investor Relations and Corporate Communications
ccargill@sosei.com

Citigate Dewe Rogerson (for international media) +44 (0) 20 7638 9571
David Dible
Mark Swallow
sosei@citigatedewerogerson.com

About Sosei

Sosei is an international biopharmaceutical company focused on the design and development of new medicines originating from its proprietary GPCR-targeted StaR® technology and structure-based drug design platform capabilities. The Company is advancing a broad and deep pipeline of partnered and wholly owned product candidates in multiple therapeutic areas, including CNS, cancer, metabolic diseases and other rare/specialty indications. The Company's leading clinical programs include a proprietary Phase 2 candidate for dementia with Lewy bodies (DLB) in Japan, together with partnered candidates aimed at the symptomatic treatment of Alzheimer's disease (with Allergan) and immuno-oncology approaches to treat cancer (with AstraZeneca). Sosei's additional partners and collaborators include Novartis, Pfizer, Daiichi-Sankyo, PeptiDream, Kymab and MorphoSys. The Company is headquartered in Japan with R&D facilities in the UK.

Sosei is listed on the Mothers Index of the Tokyo Stock Exchange (ticker: 4565). For more information, please visit http://www.sosei.com/en/.